MetaCap

Azitra (AZTR) vs Medicus Pharma (MDCX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicus Pharma is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZTR+291.52%MDCX+608.49%
+2244%+1044%-155%
Oct 7, 20261 yearNov 20, 2026
AZTR+297.84%MDCX+1132.36%
+3602%+1692%-219%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZTR versus MDCX key metrics
MetricAZTRMDCX
Share price$0.5168$1.14
Market cap$3.13M$3.16M
1-day change-2.75%-2.16%
YTD return—-25.82%
1-year return—-46.71%
EPS (TTM)$-12.40$-76.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-10.96M$-47.28M
52-week high$3.91$114.00
52-week low$0.5086$1.06
Distance from 52-week high-86.78%-99.00%
Analyst consensusbuynone
Avg. price target upside+29.64%+296.48%
Average volume2.65M116.55K
Shares outstanding6.06M2.79M
Employees1316
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Azitra

AZTR stock →

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Medicus Pharma

MDCX stock →

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

AZTR vs MDCX FAQ

Which is bigger, Azitra or Medicus Pharma?

Medicus Pharma (MDCX) is larger, with a market capitalization of $3.16M compared with $3.13M for Azitra (AZTR).

Are Azitra and Medicus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons